Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada in a research report issued on Thursday.
SHPG has been the topic of a number of other reports. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Barclays PLC lowered Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Evercore ISI began coverage on Shire PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 price target on the stock. Piper Jaffray Companies set a $159.00 price target on Shire PLC and gave the company a “hold” rating in a report on Wednesday, July 26th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $245.00 price target on shares of Shire PLC in a report on Sunday, October 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $212.18.
Shares of Shire PLC (NASDAQ:SHPG) opened at $147.37 on Thursday. The company has a market capitalization of $43,610.00, a PE ratio of 9.58, a PEG ratio of 0.77 and a beta of 1.60. Shire PLC has a twelve month low of $137.17 and a twelve month high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. The company had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter last year, the firm earned $3.17 earnings per share. sell-side analysts anticipate that Shire PLC will post 15 EPS for the current year.
Large investors have recently added to or reduced their stakes in the business. Hartford Financial Management Inc. raised its stake in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares during the period. YorkBridge Wealth Partners LLC raised its stake in Shire PLC by 81.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares during the period. BB&T Investment Services Inc. raised its stake in Shire PLC by 1,672.3% in the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 786 shares during the period. Pacer Advisors Inc. bought a new stake in Shire PLC in the second quarter valued at approximately $171,000. Finally, Stephens Inc. AR raised its stake in Shire PLC by 22.2% in the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares during the period. Hedge funds and other institutional investors own 18.27% of the company’s stock.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.